Remepy

9 stories about Remepy
מימין אור שובל וד"ר מיכל צור מנכ"לים משותפים של Remepy

Remepy raises $36 million Series A as it prepares AI-driven Parkinson’s treatment for Phase III

12.08.26|Meir Orbach
The Israeli company’s Hybridopa program has shown improvements in motor and non-motor symptoms in Phase IIa trials, while a new partnership with Merck is expanding its approach into rare tumors. 
מימין סתיו לי נוימרק מאור לברן מיכל צור רועי קתמור קומרה ניו יורק 2026

The Israeli startups to watch out for in 2026

13.05.26|Meir Orbach
Eleven companies spanning AI, cybersecurity, fintech and health tech are shaping Israel’s next wave of growth-stage innovation.
Remepy founders

Merck KGaA and Remepy partner to test ‘Hybrid Drugs’ model

28.04.26|Meir Orbach
Collaboration explores combining medication with app-based therapies in rare tumor programs. 
אור שובל אמיר עמדי ו מיכל צור רמפי

Remepy raises $10 million Seed round to bring first hybrid drug to market

01.05.24|Meir Orbach
The Israeli startup’s new hybrid drugs combine traditional drugs with its “digital molecules.” Digital molecules are therapeutic interventions that trigger physiological effects through the brain